Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4956336 | 1.00 | LTA4H (0.41) | LTA4HGPR84 | |
| SCHEMBL4957238 | 0.84 | LTA4H (0.39) | LTA4HGPR84 | |
| SCHEMBL7004251 | 0.83 | LTA4H (0.41) | LTA4H | |
| SCHEMBL4958489 | 0.80 | LTA4H (0.48) | LTA4H | |
| SCHEMBL4957361 | 0.78 | LTA4H (0.47) | LTA4H | |
| SCHEMBL4957374 | 0.78 | LTA4H (0.47) | LTA4H | |
| SCHEMBL4957198 | 0.77 | ADRA1D (0.43) | LTA4H | |
| SCHEMBL4955920 | 0.76 | HPGD (0.43) | LTA4H | |
| SCHEMBL4955935 | 0.76 | HPGD (0.43) | LTA4H | |
| SCHEMBL7275192 | 0.73 | ALOX5 (0.41) | LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423048-B2 | Compounds for treating fundic disaccomodation | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-09 | — | — | US | disclosed |
| US-7081453-B2 | Compounds for treating impaired fundic relaxation | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-25 | — | — | US | disclosed |
| US-20060142318-A1 | Compounds for treating fundic disaccomodation | VAN EMELEN KRISTOF | 2006-06-29 | — | — | US | disclosed |
| EP-1296987-B1 | COMPOUNDS FOR TREATING IMPAIRED FUNDIC RELAXATION | JANSSEN PHARMACEUTICA NV (BE) | 2005-12-07 | — | — | EP | disclosed |
| US-20040019051-A1 | Compounds for treating impaired fundic relaxation | JANSSEN-CILAG S.A. (ES) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019051-A1 | Compounds for treating impaired fundic relaxation | CNR2, CNR1, CBR1 | LTA4H 1504/4885GPR84 999/4885 |
| US-20060142318-A1 | Compounds for treating fundic disaccomodation | ALK, ADORA1, CHRM2 | LTA4H 1162/4885GPR84 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.